Theophylline isopropanolamine | 5600-19-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: Theophylline isopropanolamine
• 英文别名: 1-aminopropan-2-ol;1,3-dimethyl-7H-purine-2,6-dione
• CAS: 5600-19-1
• 化学式: C10H17N5O3
• 分子量: 255.27
• InChiKey: QFJDTNNSYMKICD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.71
• 重原子数：
  18
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  116
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• Sustained release tablet comprising pramipexole
  申请人：Pharmacia Corporation

  公开号：EP2172199A1

  公开（公告）日：2010-04-07

  A sustained - release pharmaceutical composition in a form of an orally deliverable tablet comprising an active pharmaceutical agent having solubility not less than about 10mg/ml, dispersed in a matrix comprising a hydrophilic polymer and a starch having a tensile strength of at least about 0.15kNcm-2 at a solid fraction representative of the tablet.

  一种口服给药片剂形式的缓释药物组合物，包含溶解度不小于约 10 毫克/毫升的活性药剂，分散在由亲水性聚合物和淀粉组成的基质中，在片剂的代表性固体部分拉伸强度至少约为 0.15 千牛顿厘米-2。
• Methylxanthines in the diagnosis and treatment of autistic disorder
  申请人：——

  公开号：US20020019407A1

  公开（公告）日：2002-02-14

  The invention is based on the discovery that the levels of one or more methylxanthines in urine samples are significantly decreased in children diagnosed with symptoms of autistic disorder, compared to the levels in normal children, and that levels of xanthines in urine are increased in autistic children. Consequently, the presence in the urine of levels of methylxanthines below a certain range and the level of xanthine above a certain range, are diagnostic of autistic disorder. In another aspect, one or more of these methylxanthines can be used to treat individuals exhibiting symptoms of autistic disorder.

  本发明基于以下发现：与正常儿童相比，确诊有自闭症症状的儿童尿样中一种或多种甲基黄嘌呤的含量明显降低，而自闭症儿童尿样中黄嘌呤的含量升高。因此，尿液中甲基黄嘌呤含量低于一定范围，黄嘌呤含量高于一定范围，可诊断为自闭症。另一方面，这些甲基黄嘌呤中的一种或多种可用于治疗表现出自闭症症状的个体。
• Sustained-release tablet composition
  申请人：Amidon E. Gregory

  公开号：US20070196481A1

  公开（公告）日：2007-08-23

  A sustained-release pharmaceutical composition in a form of an orally deliverable tablet comprises an active pharmaceutical agent having solubility not less than about 10 mg/ml, dispersed in a matrix comprising a hydrophilic polymer and a starch having a tensile strength of at least about 0.15 kN cm −2 at a solid fraction representative of the tablet.
• SUSTAINED-RELEASE TABLET COMPOSITION
  申请人：Amidon Gregory E.

  公开号：US20090143387A1

  公开（公告）日：2009-06-04

  A sustained-release pharmaceutical composition in a form of an orally deliverable tablet containing reboxetine, or a pharmaceutically acceptable salt thereof, dispersed in a matrix containing a hydrophilic polymer and a starch, wherein the starch has a tensile strength of at least 0.15 kN cm −2 at a solid fraction of 0.75 to 0.85.
• US4783337A
  申请人：——

  公开号：US4783337A

  公开（公告）日：1988-11-08